Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

BACKGROUND. This SafeHer subgroup analysis assessed the safety of fixed‐dose subcutaneous trastuzumab (H SC) as an adjuvant therapy in HER2‐positive early breast cancer (EBC) by body weight. PATIENTS AND METHODS. Patients with HER2‐positive EBC not previously treated with anti‐HER2 therapy received...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Jung, Kyung Hae, Ataseven, Beyhan, Verrill, Mark, Pivot, Xavier, De Laurentiis, Michelino, Al‐Sakaff, Nedal, Lauer, Sabine, Shing, Mona, Gligorov, Joseph, Azim, Hamdy A.
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2018
Teme:
Breast Cancer
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6263135/
https://ncbi.nlm.nih.gov/pubmed/30018134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0065
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items